News
ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines
May 04, 2021
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine...
Read more
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
May 03, 2021
First patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of pa...
Read more
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy - Nucleic Acids and Oncotarget
March 24, 2021
Results further support the potential of lead candidate, INT-1B3, as novel option for
therapeutic intervention in oncology
Read more
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
March 11, 2021
This award will support the clinical validation of the Company's lead candidate, INT-1B3, for the treatment of solid tumors.
Read more
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
March 05, 2021
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patie...
Read more
ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy
March 03, 2021
ISA106's promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-1...
Read more
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
February 16, 2021
-- Phase 1 study to investigate safety and preliminary efficacy of lead candidate, INT-1B3 --
Read more
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
February 12, 2021
Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
February 09, 2021
-- Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic --
Read more
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®
January 26, 2021
Combination aimed at priming and driving durable patient immune responses to cancer
Read more
